Shattuck Labs, Inc. (STTK)

NASDAQ: STTK · IEX Real-Time Price · USD
1.96
0.00 (0.00%)
Dec 1, 2023, 4:30 PM EST - Market closed
0.00%
Market Cap 83.27M
Revenue (ttm) 1.33M
Net Income (ttm) -95.02M
Shares Out 42.49M
EPS (ttm) -2.24
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 29,581
Open 1.81
Previous Close 1.96
Day's Range 1.81 - 1.98
52-Week Range 1.33 - 4.77
Beta 1.21
Analysts Strong Buy
Price Target 20.00 (+920.41%)
Earnings Date Nov 9, 2023

About STTK

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. The company was incorporated in 2016 and is headquartered in Austin, Texas. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 9, 2020
Employees 105
Stock Exchange NASDAQ
Ticker Symbol STTK
Full Company Profile

Financial Performance

In 2022, Shattuck Labs's revenue was $652,000, a decrease of -97.83% compared to the previous year's $30.02 million. Losses were -$101.95 million, 126.7% more than in 2021.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for STTK stock is "Strong Buy." The 12-month stock price forecast is $20.0, which is an increase of 920.41% from the latest price.

Price Target
$20.0
(920.41% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Shattuck Labs Announces Participation in Upcoming 6th Annual Evercore ISI HealthCONx Conference

AUSTIN, TX & DURHAM, NC, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion prot...

19 days ago - GlobeNewsWire

Shattuck Labs Reports Third Quarter 2023 Financial Results and Recent Business Highlights

– Positive interim data from Phase 1B clinical trial of SL-172154 in combination with pegylated liposomal doxorubicin (PLD) in platinum-resistant ovarian cancer (PROC) demonstrated an acceptable safet...

24 days ago - GlobeNewsWire

Shattuck Labs to Report Third-Quarter 2023 Financial Results on November 9, 2023

AUSTIN, TX and DURHAM, NC, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion pr...

27 days ago - GlobeNewsWire

Shattuck Labs to Present Topline Data from Phase 1 A/B Clinical Trial of SL-172154 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS) Patients at the American Society of Hematology (ASH) 2023 Annual Meeting

– SL-172154 as monotherapy and in combination with azacitidine demonstrates anti-leukemic activity and an acceptable safety and tolerability profile –

4 weeks ago - GlobeNewsWire

Shattuck Labs Reports Second Quarter 2023 Financial Results and Recent Business Highlights

– Presented complete data from Phase 1A clinical trial of SL-172154 as monotherapy in platinum-resistant ovarian cancer (PROC) at the American Society of Clinical Oncology (ASCO) 2023 annual meeting, ...

4 months ago - GlobeNewsWire

Shattuck Labs to Present Complete Dose-Escalation Data from Phase 1A Monotherapy Clinical Trial of SL-172154 in Platinum-Resistant Ovarian Cancer (PROC) at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

- SL-172154 demonstrated favorable safety and tolerability profile across doses, with maximal CD47 and CD40 target engagement and CD40-dependent pharmacodynamic effects observed at the 3 mg/kg dose –

6 months ago - GlobeNewsWire

Shattuck Labs Reports First Quarter 2023 Financial Results and Recent Business Highlights

— Complete data from Phase 1A clinical trial of SL-172154 as monotherapy in platinum-resistant ovarian cancer (PROC) to be presented at the 2023 American Society of Clinical Oncology (ASCO) annual mee...

7 months ago - GlobeNewsWire

Shattuck Labs Announces Participation in Upcoming 22nd Annual Needham Virtual Healthcare Conference

AUSTIN, TX and DURHAM, NC, April 03, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion p...

8 months ago - GlobeNewsWire

Shattuck Labs Presents Preclinical Data at the 2023 American Association for Cancer Research (AACR) Annual Meeting

– CD20-targeted GADLEN demonstrated preclinical proof of concept of rapid B cell depletion in humanized mice and non-human primates, intended for clinical development in autoimmune disease –

9 months ago - GlobeNewsWire

Shattuck Labs Announces Participation in Upcoming March Conferences

AUSTIN, TX and DURHAM, NC, March 01, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion p...

9 months ago - GlobeNewsWire

Shattuck Labs Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Business Updates

– Initiated enrollment in Phase 1B clinical trial of SL-172154 in combination with mirvetuximab soravtansine in platinum-resistant ovarian cancer –

10 months ago - GlobeNewsWire

Shattuck Labs to Report Fourth-Quarter and Full-Year 2022 Financial Results on February 23, 2023

AUSTIN, TX & DURHAM, NC, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion prot...

10 months ago - GlobeNewsWire

Shattuck Labs Announces Participation in Upcoming SVB Securities Global Biopharma Conference

AUSTIN, TX & DURHAM, NC, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion prot...

10 months ago - GlobeNewsWire

Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2023

AUSTIN, TX & DURHAM, NC, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion prot...

11 months ago - GlobeNewsWire

Shattuck Labs Reports Third Quarter 2022 Financial Results and Recent Business Highlights

– Completed enrollment in Phase 1 dose-escalation clinical trial of SL-172154 as monotherapy in platinum-resistant ovarian cancer; complete data expected midyear 2023 –

1 year ago - GlobeNewsWire

Shattuck Labs Presents Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

- Data from two distinct GADLEN product candidates, one targeting CD20 and another targeting B7-H3, enhanced γδT cell killing of tumor cells, demonstrating preclinical proof-of-concept in the treatmen...

1 year ago - GlobeNewsWire

Shattuck Labs Announces Participation in Upcoming November Conferences

AUSTIN, TX and DURHAM, NC, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion pr...

1 year ago - GlobeNewsWire

Shattuck Labs to Report Third Quarter 2022 Financial Results on November 8, 2022

AUSTIN, TX and DURHAM, NC, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion pr...

1 year ago - GlobeNewsWire

Shattuck Labs to Present Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting November 8-12

AUSTIN, TX & DURHAM, NC, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion prot...

1 year ago - GlobeNewsWire

Shattuck Labs Announces Participation in Upcoming September Conferences

AUSTIN, TX & DURHAM, NC, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion pro...

1 year ago - GlobeNewsWire

Shattuck Labs Reports Second Quarter 2022 Financial Results and Recent Business Highlights

– Enrollment of Phase 1B clinical trial of SL-172154 in combination with liposomal doxorubicin in platinum-resistant ovarian cancer expected to begin in Q3'2022 with initial combination data expected ...

1 year ago - GlobeNewsWire

Shattuck Labs Reports First Quarter 2022 Financial Results and Recent Business Highlights

– Dose escalation ongoing in Phase 1 clinical trial of SL-172154 in platinum-resistant ovarian cancer; combination trial with liposomal doxorubicin on track to begin in 2H'2022; full dose-escalation d...

1 year ago - GlobeNewsWire

Shattuck Labs Presents Preclinical Data at the 2022 American Association for Cancer Research (AACR) Annual Meeting

- SL-9258 (TIGIT-Fc-LIGHT) combined with anti-PD(L)1 broadened anti-tumor activity of the checkpoint antibodies in aggressive CPI-resistant tumors -

1 year ago - GlobeNewsWire

Shattuck Labs Announces Participation in Upcoming 21st Annual Needham Virtual Healthcare Conference

AUSTIN, TX and DURHAM, NC, April 05, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as ...

1 year ago - GlobeNewsWire

SHATTUCK ALERT: Bragar Eagel & Squire, P.C. is Investigating Shattuck Labs, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)-- #Class--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Shattuck Labs, Inc. (NASDAQ: STTK) on be...

1 year ago - Business Wire